Chromatin Remodeling Enzyme Cluster Predicts Prognosis and Clinical Benefit of Therapeutic Strategy in Breast Cancer

doi:10.3390/ijms24065583

Chia Nan University of Pharmacy & Science Institutional Repository > 行政單位 > 456 > Item 310902800/34822

請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34822

標題:	Chromatin Remodeling Enzyme Cluster Predicts Prognosis and Clinical Benefit of Therapeutic Strategy in Breast Cancer
作者:	Kuo, Chia-Yu Moi, Sin-Hua Hou, Ming-Feng Luo, Chi-Wen Pan, Mei-Ren
貢獻者:	Kaohsiung Med Univ Hosp, Dept Surg, Div Breast Oncol & Surg Kaohsiung Med Univ, Grad Inst Med, Coll Med Kaohsiung Med Univ, Grad Inst Clin Med Kaohsiung Med Univ, Res Ctr Precis Environm Med Kaohsiung Med Univ, Coll Life Sci, Dept Biomed Sci & Environm Biol Chia Nan Univ Pharm & Sci, Dept Cosmet Sci Chia Nan Univ Pharm & Sci, Inst Cosmet Sci Kaohsiung Med Univ Hosp, Ctr Canc Res Kaohsiung Med Univ, Drug Dev & Value Creat Res Ctr
關鍵字:	chromatin remodeling enzyme epigenetic modification chemotherapy radiotherapy hierarchical clustering
日期:	2023
上傳時間:	2024-12-25 11:04:04 (UTC+8)
出版者:	MDPI
摘要:	The treatment provided for breast cancer depends on the expression of hormone receptors, human epidermal growth factor receptor-2 (HER2), and cancer staging. Surgical intervention, along with chemotherapy or radiation therapy, is the mainstay of treatment. Currently, precision medicine has led to personalized treatment using reliable biomarkers for the heterogeneity of breast cancer. Recent studies have shown that epigenetic modifications contribute to tumorigenesis through alterations in the expression of tumor suppressor genes. Our aim was to investigate the role of epigenetic modifications in genes involved in breast cancer. A total of 486 patients from The Cancer Genome Atlas Pan-cancer BRCA project were enrolled in our study. Hierarchical agglomerative clustering analysis further divided the 31 candidate genes into 2 clusters according to the optimal number. Kaplan-Meier plots showed worse progression-free survival (PFS) in the high-risk group of gene cluster 1 (GC1). In addition, the high-risk group showed worse PFS in GC1 with lymph node invasion, which also presented a trend of better PFS when chemotherapy was combined with radiotherapy than when chemotherapy was administered alone. In conclusion, we developed a novel panel using hierarchical clustering that high-risk groups of GC1 may be promising predictive biomarkers in the clinical treatment of patients with breast cancer.
關聯:	International Journal of Molecular Sciences, v.24, n.6, Article 5583
顯示於類別:	[行政單位] 456

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
index.html		0Kb	HTML	0	檢視/開啟

在CNU IR中所有的資料項目都受到原著作權保護.

TAIR相關文章

資料載入中.....